Protegrin-1 (PG-1)
Protegrin-1 is an 18-amino acid beta-hairpin antimicrobial peptide from porcine leukocytes, featuring two disulfide bonds and potent broad-spectrum antimicrobial activity through membrane pore formation. Its synthetic analog iseganan (IB-367) has been evaluated in clinical trials.
Overview
Protegrins were discovered during a systematic search for antimicrobial peptides in porcine neutrophils, yielding five closely related peptides (PG-1 through PG-5). PG-1, the most extensively studied member, is remarkable for its combination of small size, structural rigidity, and exceptional antimicrobial potency. Unlike the flexible alpha-helical antimicrobial peptides (such as LL-37 and magainins), PG-1 adopts a pre-formed beta-hairpin structure in solution that is maintained by two disulfide bonds and a beta-turn. This rigid structure allows PG-1 to rapidly insert into membranes and form octameric transmembrane pores without requiring the conformational transition that alpha-helical peptides must undergo.
PG-1 exhibits minimum inhibitory concentrations (MICs) in the low micromolar range against clinically important pathogens including MRSA, vancomycin-resistant Enterococcus (VRE), Pseudomonas aeruginosa, Acinetobacter baumannii, and Candida species. This broad-spectrum activity, combined with a rapid killing mechanism fundamentally different from conventional antibiotics, made protegrin an attractive template for antimicrobial drug development.
Mechanism of Action
PG-1 kills microorganisms through a well-characterized membrane disruption mechanism:
- Electrostatic binding: The high cationic charge (+7) of PG-1 drives initial binding to anionic microbial membrane surfaces through electrostatic interactions with phosphatidylglycerol, cardiolipin, and LPS Fahrner et al. (1996).
- Membrane insertion: The amphipathic beta-hairpin structure allows PG-1 to insert into the lipid bilayer with its hydrophobic face oriented toward lipid acyl chains and its cationic arginine residues interacting with anionic lipid headgroups.
- Octameric pore formation: Molecular dynamics simulations and experimental studies demonstrate that PG-1 forms transmembrane pores composed of 8–10 monomers arranged in a barrel-stave-like configuration. These pores allow uncontrolled ion flux, membrane depolarization, and cell death within minutes Langham et al. (2008).
- LPS binding: PG-1 binds directly to lipopolysaccharide in gram-negative outer membranes, facilitating outer membrane permeabilization as a prerequisite to inner membrane pore formation Mani et al. (2006).
- Rapid killing kinetics: PG-1 kills bacteria within 5–15 minutes at MIC concentrations, far faster than conventional antibiotics. This rapid action limits the window for resistance development through adaptive mechanisms.
Reconstitution Calculator
Research
Broad-Spectrum Antimicrobial Activity
PG-1 exhibits potent activity against a wide range of clinically important pathogens. Steinberg et al. demonstrated MIC values of 0.12–4 μg/mL against S. aureus (including MRSA), E. coli, P. aeruginosa, K. pneumoniae, and C. albicans. Notably, PG-1 retains activity in the presence of physiological salt concentrations and serum, a significant advantage over many other antimicrobial peptides Steinberg et al. (1997).
Membrane Pore Formation
The transmembrane pore formed by PG-1 has been characterized by solid-state NMR, molecular dynamics simulations, and electrophysiology. Mani et al. used solid-state NMR to show that PG-1 is oriented perpendicular to the membrane plane, consistent with a transmembrane barrel-stave pore model. The pore has an estimated inner diameter of ~21 Å, sufficient to allow passage of small molecules and ions, causing rapid depolarization and osmotic lysis Mani et al. (2006).
Activity Against Antibiotic-Resistant Bacteria
PG-1's membrane-disrupting mechanism is fundamentally different from conventional antibiotics, making cross-resistance unlikely. PG-1 retains full activity against MRSA, VRE, extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae, and carbapenem-resistant A. baumannii. This has renewed interest in protegrin-derived peptides as templates for next-generation antimicrobials targeting multidrug-resistant infections Tam et al. (2000).
Iseganan (IB-367) Clinical Trials
Iseganan (IB-367), a synthetic protegrin analog, was developed by IntraBiotics Pharmaceuticals for prevention of oral mucositis in patients undergoing chemotherapy or radiation therapy. The rationale was that antimicrobial peptide-mediated reduction of oral microbial load would prevent secondary infections of radiation-damaged oral mucosa.
- Phase II trials: Iseganan oral rinse (9 mg/mL, used 6 times daily) showed promise in reducing the severity and duration of oral mucositis in patients receiving stomatotoxic chemotherapy Mosca et al. (2000).
- Phase III trials: Two large Phase III trials for prevention of oral mucositis in head and neck cancer patients receiving radiation therapy failed to meet primary endpoints, showing no significant difference from placebo in mucositis prevention. The failure was attributed to insufficient drug contact time and the complexity of mucositis pathogenesis beyond microbial factors Trotti et al. (2004).
- Ventilator-associated pneumonia: A Phase III trial of aerosolized iseganan for prevention of ventilator-associated pneumonia was terminated early due to a trend toward increased mortality in the treatment group, raising concerns about the safety of aerosolized antimicrobial peptides in critically ill patients Kollef et al. (2006).
Membrane-disrupting antimicrobial peptide
Protegrin-1 (PG-1) is a porcine cathelicidin-derived, beta-hairpin, disulfide-stabilized cationic peptide that rapidly permeabilizes microbial membranes with broad-spectrum, fast bactericidal activity and low resistance selection.
- IB-367/iseganan kills MRSA and P. aeruginosa within minutes at near-MIC concentrations
- Speed of killing and breadth of spectrum make it a model AMP scaffold
Clinical translation limits
Despite strong preclinical activity, the optimized analog iseganan failed phase III oral mucositis trials, largely because bacterial colonization is not the sole driver of mucositis and mammalian-cell toxicity constrains dosing.
- Two phase III oral mucositis programs (chemo and radiotherapy) missed primary endpoints
- Host-cell toxicity remains a barrier for systemic protegrin therapeutics
Safety Profile
PG-1 and its analogs present notable safety considerations due to the potent membrane-active mechanism:
- Hemolytic activity: PG-1 exhibits significant hemolytic activity at concentrations near its MIC, resulting in a narrow therapeutic index. HC₅₀ (concentration causing 50% hemolysis) is approximately 50–100 μg/mL, only 10–50 fold above MIC values for sensitive organisms.
- Cytotoxicity: Dose-dependent toxicity to mammalian cells has been observed, attributed to the peptide's potent membrane-disrupting mechanism and inability to fully discriminate between microbial and host cell membranes at higher concentrations.
- Clinical safety signals: The Phase III VAP trial of aerosolized iseganan was terminated due to a trend toward increased mortality, though causality was not established. This raised concerns about systemic or pulmonary toxicity of protegrin analogs.
- Topical safety: Iseganan was generally well-tolerated as an oral rinse in clinical trials, with local adverse effects (taste disturbance, mild mucosal irritation) being the primary complaints.
- Resistance potential: While protegrin resistance is theoretically difficult due to the membrane-targeting mechanism, some bacteria can modify membrane lipid composition or upregulate efflux pumps to reduce susceptibility.
Pharmacokinetic Profile
Quick Start
- Route
- Topical (research), Oral rinse (iseganan clinical trials)
Molecular Structure
- Formula
- C₈₆H₁₄₂N₃₆O₂₀S₄
Research Indications
Investigational / Research Areas
The protegrin-1 analog iseganan was tested in phase III trials for chemo- and radiotherapy-induced oral mucositis; safe but did not meet primary endpoints.
Protegrin-1 rapidly kills Gram-positive and Gram-negative bacteria (including MRSA) and fungi via membrane permeabilization.
Studied for oral, respiratory, and topical infection control given rapid killing and low resistance.
Research Protocols
topical
- Topical safety: Iseganan was generally well-tolerated as an oral rinse in clinical trials, with local adverse effects (taste disturbance, mild mucosal irritation) being the primary complaints.
| Goal | Dose | Frequency | Duration |
|---|---|---|---|
| General Research Protocol | 0.12–4 μg | Per protocol | — |
| Sensitive organisms | 50–100 μg | Per protocol | — |
oral
Iseganan (IB-367) Clinical Trials Iseganan (IB-367), a synthetic protegrin analog, was developed by IntraBiotics Pharmaceuticals for prevention of oral mucositis in patients undergoing chemotherapy or radiation therapy. The rationale was that antimicrobial peptide-mediated reduction of oral microbi
| Goal | Dose | Frequency | Duration |
|---|---|---|---|
| Hemolytic activity | 50–100 μg | Per protocol | — |
| Phase II trials | 9 mg | Daily | —(Route: Oral) |
Quality Indicators
What to look for
- Phase 3 clinical trial data available
- Well-established safety profile
- Multiple peer-reviewed studies available
Frequently Asked Questions
References (14)
- [11]Ramamoorthy A et al — Structural insights into protegrin-1 membrane interactions using solid-state NMR Biochim Biophys Acta Biomembr (2023)
- [13]Chen C et al — Rational design of protegrin-1 analogs with enhanced antimicrobial activity and reduced hemolytic toxicity ACS Infect Dis (2022)
- [1]Kokryakov VN, Harwig SS, Panyutich EA, et al Protegrins: leukocyte antimicrobial peptides that combine features of corticostatic defensins and tachyplesins FEBS Lett (1993)
- [2]Fahrner RL, Dieckmann T, Harwig SS, et al Solution structure of protegrin-1, a broad-spectrum antimicrobial peptide from porcine leukocytes Chem Biol (1996)
- [3]Steinberg DA, Hurst MA, Fujii CA, et al Protegrin-1: a broad-spectrum, rapidly microbicidal peptide with in vivo activity Antimicrob Agents Chemother (1997)
- [4]Mani R, Cady SD, Tang M, et al Membrane-dependent oligomeric structure and pore formation of a beta-hairpin antimicrobial peptide in lipid bilayers from solid-state NMR Proc Natl Acad Sci USA (2006)
- [6]Mosca DA, Hurst MA, So W, et al IB-367, a protegrin peptide with in vitro and in vivo activities against the microflora associated with oral mucositis Antimicrob Agents Chemother (2000)
- [7]Trotti A, Garden A, Warde P, et al A multinational, randomized phase III trial of iseganan HCl oral solution for reducing the severity of oral mucositis in patients receiving radiotherapy for head-and-neck malignancy Int J Radiat Oncol Biol Phys (2004)
- [8]Kollef M, Pittet D, Sánchez-García M, et al A randomized double-blind trial of iseganan in prevention of ventilator-associated pneumonia Am J Respir Crit Care Med (2006)
- [9]Tam JP, Lu YA, Yang JL Marked increase in membranolytic selectivity of novel cyclic tachyplesins constrained with an antiparallel two-beta strand cystine knot framework Biochem Biophys Res Commun (2000)
- [5]Langham AA, Ahmad AS, Bhaya B, Kaznessis YN On the nature of antimicrobial activity: a model for protegrin-1 pores J Am Chem Soc (2008)
- [10]Edwards IA et al — Contribution of amphipathicity and hydrophobicity to the antimicrobial activity and cytotoxicity of protegrin analogues Molecules (2022)
- [12]Bolatchiev A — Antimicrobial peptides as next-generation therapeutics against antibiotic-resistant bacteria: current and future perspectives Front Microbiol (2024)
- [14]A phase III, randomized, placebo-controlled trial of iseganan for prevention of oral mucositis in patients receiving stomatotoxic chemotherapy (PROMPT-CT) (2003)
→ Iseganan (protegrin-1 analog) did not significantly reduce oral mucositis incidence at the primary endpoint (P=.067) but improved some secondary symptom measures.
Protection of Telomeres 1 (POT1) Peptide
POT1 (Protection of Telomeres 1) peptides are synthetic compounds designed to modulate the function of POT1, a critical component of the six-protein shelterin c
Prucalopride
Prucalopride is a selective, high-affinity 5-HT4 receptor agonist used primarily as a prokinetic agent for treating chronic constipation. It works by stimulatin